Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005

JAMA

Volumn 295, Issue 19, 2006, Pages 2270-2274

  Ridker, Paul M ^a   Torres, Jose ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAPROXEN; PRAVASTATIN; ROFECOXIB; SIMVASTATIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANGIOGRAPHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FUNDING; HEALTH CARE; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; ULTRASOUND;

EID: 33646679623     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.19.2270     Document Type: Review

References (40)

1. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal antiinflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154:157-163.
2. Wahlbeck K, Adams C. Beyond conflict of interest: sponsored drug trials show more-favourable outcomes. BMJ. 1999;318:465.
3. Kjaergard LL, Nikolova D, Glaud C. Randomized clinical trials in hepatology: predictors of quality. Hepatology. 1999;30:1134-1138.
4. Djulbegovic B, Bennett CL, Lyman G. Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoietin (EPO). Blood. 1999;94:399a.
5. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet. 2000;356:635-638.
6. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomized clinical trials published in the BMJ. BMJ. 2002;325:249-252.
7. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trial: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-928.
8. Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004;170:477-480.
9. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-465.
10. Chan AW, Hrobjartsson A, Hahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291:2457-2465.
11. Rennie D. Fair conduct and fair reporting of clinical trials. JAMA. 1999;282:1766-1768.
12. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
13. Miller PB, Weijer C. Rehabilitating equipoise. Kennedy Inst Ethics J. 2003;13:93-118.
14. Olson LG. Patient-centered equipoise and the ethics of randomized controlled trials. Monash Bioeth Rev. 2002;21:S55-S67.
15. Gifford F. Community-equipoise and the ethics of randomized clinical trials. Bioethics. 1995;9:127-148.
16. Montaner JS, O'Shaughnessy MV, Schecter MT. Industry-sponsored research: a double-edged sword. Lancet. 2001;358:1893-1895.
17. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med. 2000;342:1539-1544.
18. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Ann Intern Med. 2004;141:477-478.
19. Zarin DA, Tse T, Ide NC. Trial registration at ClincalTrials.gov between May and October 2005. N Engl J Med. 2005;353:2779-2787.
20. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
21. Ridker PM, Goldhaber SZ, Danielson E, et al. Longterm, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434.
22. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
23. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:56-65.
24. Fries JF, Krishnan E. Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development. Arthritis Res Ther. 2004;6:R250-R255.
25. Topol EJ, Moliterno DJ, Herrmann HC, et al; TARGET Investigators. Comparison of two glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
26. Cannon CP, Braunwald E, McCabe CH, et al; for the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
27. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis," N Engl J Med 2000;343:1520-8. N Engl JMed. 2005;353:2813-2814.
28. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvasatin Survival Study (4S). Lancet. 1994;344:1383-1389.
29. The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
30. The Long-Term Intervention with Pravastatin Group in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
31. Shepherd J, Cobbe SM, Ford I, et al; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
32. Downs JR, Clearfield M, Weis S, et al; for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
33. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
34. Sever PS, Dahlof B, Poulter NR, et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
35. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid-lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
36. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
37. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [published online ahead of print March 12, 2006]. N Engl J Med. 2006;354:1706-1717.
38. Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis [published online ahead of print March 13, 2006]. JAMA. 2006;295:1556-1565.
39. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-323.
40. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.